Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC

NCT06890182 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Firmonertinib combined with Carboplatin/Cisplatin and Pemetrexed

Sponsor

Tianjin Medical University Cancer Institute and Hospital